SQZ Biotechnologies (NYSE:SQZ – Get Rating) released its quarterly earnings results on Thursday. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.01), Fidelity Earnings reports. SQZ Biotechnologies had a negative return on equity of 57.79% and a negative net margin of 303.43%.
SQZ Biotechnologies Trading Up 4.6 %
Shares of NYSE:SQZ traded up $0.15 during mid-day trading on Friday, reaching $3.39. The stock had a trading volume of 79,992 shares, compared to its average volume of 49,626. The firm has a market cap of $95.43 million, a PE ratio of -1.28 and a beta of 2.65. The firm has a 50 day simple moving average of $3.25 and a two-hundred day simple moving average of $4.31. SQZ Biotechnologies has a twelve month low of $2.61 and a twelve month high of $16.17.
Wall Street Analyst Weigh In
Separately, Chardan Capital began coverage on shares of SQZ Biotechnologies in a research report on Wednesday, May 25th. They set a “buy” rating and a $17.00 target price on the stock.
Insider Buying and Selling
Hedge Funds Weigh In On SQZ Biotechnologies
A hedge fund recently raised its stake in SQZ Biotechnologies stock. Charles Schwab Investment Management Inc. raised its holdings in shares of SQZ Biotechnologies (NYSE:SQZ – Get Rating) by 7.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,693 shares of the company’s stock after purchasing an additional 4,196 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.22% of SQZ Biotechnologies worth $292,000 at the end of the most recent reporting period. Institutional investors own 66.56% of the company’s stock.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
- Get a free copy of the StockNews.com research report on SQZ Biotechnologies (SQZ)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.